Alcon


Q2 story: Innovation is being well received by the end market

11/08/26 -"The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, which were able to comfortably offset the ..."

Pages
53
Language
English
Published on
11/08/26
You may also be interested by these reports :
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...

06/08/26
Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. ...

06/08/26
CZM’s Q3 results exceeded expectations, with top-line growth driven by strong performance in Microsurgery. Ophthalmology showed modest growth. The ...

06/08/26
FMC delivered better-than-expected Q2 26 results on revenue and adjusted EBIT, though the margin beat was heavily reimbursement-driven and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO